New drug candidate shows promise against cancer
Platinum compound may offer an alternative to cisplatin, a widely used chemotherapy agent.
Predicting how proteins will partner
Amy Keating models critical interactions that underlie most cellular functions.
Continuous drug manufacturing offers speed, lower costs
New system developed by MIT researchers could help transform the pharmaceutical industry.
Successful human tests for first wirelessly controlled drug-delivery chip
Clinical trial of the programmable, implantable device shows promise in treating osteoporosis.
Moving past trial and error
Richard Braatz applies math to design new materials and processes for drug manufacturing.
Digging for answers
MIT, Pfizer hold groundbreaking for new biomedical research facility in Kendall Square.
Making a Nobel-winning chemistry reaction even better
New catalyst offers greater control over the synthesis of organic cyclic compounds, including potential cancer drugs.
Pfizer expands its research footprint in Cambridge
Announces lease of space in building being developed by MIT
Five companies join the Center for Biomedical Innovation's NEWDIGS program
Bristol‐Myers Squibb, Johnson & Johnson, Life Technologies, Pfizer and Quintiles will support initiatives in regulatory science and oncology innovation.
More than just a pretty flower
MIT chemists engineer the periwinkle plant to produce compounds that could become more effective cancer drugs.
Nerve-cell regeneration quest is fast tracked
Microchip technology rapidly identifies compounds for regrowing nerves, in live animals.
Squeezing more production out of bacteria
MIT chemical engineers demonstrate a new way to dramatically boost bacteria’s manufacturing abilities.
From sponges, a potential cancer drug
MIT chemists have synthesized a family of natural compounds that have shown promise in killing tumor cells.
Why saliva forms beads on a string
Researchers’ solution to longstanding mystery could enable better inkjet printing and drug-dispensing systems.
MIT’s Koch Institute in strategic partnership with Ortho-McNeil-Janssen Pharmaceuticals
Organizations will collaborate in multiple areas of oncology research and technology development.